Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spevatamig (PT886) in Advanced Gastrointestinal Cancers (TWINPEAK)
NCT05482893Phase 2Recruiting
- Sponsor
- Phanes Therapeutics, Inc.
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of spevatamig in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), sponsored by Phanes Therapeutics, Inc.. Started Mar 2023; status: recruiting.
02
Drugs
spevatamig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomabiliary tract cancer (BTC)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05482893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05482893.